medigraphic.com
Colegio de Medicina Interna de México.

2020, Número S2

<< Anterior Siguiente >>

Med Int Mex 2020; 36 (S2)


Esquemas de tratamiento para pacientes confirmados

Pérez-Barragán E, Cabrera-Rayo A, Cárdenas-Bravo L, Márquez-Díaz F, Rojas-Flores DM, Cadena-Orea D, Paredes-Ceballos O, De la Cruz-Hernández I

Idioma: Español
Referencias bibliográficas: 16
Paginas: 35-40
Archivo PDF: 327.32 Kb.


FRAGMENTO

RECOMENDACIONES GENERALES

• En general, restringir el tiempo de estancia en la habitación del paciente a lo estrictamente necesario.
• Los esteroides están contraindicados de manera inicial.
• Evitar nebulizaciones en espacios abiertos por el riesgo de producción de aerosoles.
• Si fuera necesario, se recomienda la administración de broncodilatadores en cartucho.
• Se recomienda el uso de puntas nasales, colocando una mascarilla quirúrgica sobre ellas. Si es necesario mascarilla reservorio y ventilación mecánica temprana.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gomersall CD, Joynt GM, Lam P, et al. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med 2004;30(3):381-387. doi:10.1007/s00134-003-2143-y.

  2. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy [published online ahead of print, 2020 Mar 27]. J Thromb Haemost 2020;10.1111/jth.14817. doi:10.1111/jth.14817.

  3. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13]. JAMA Intern Med 2020;e200994. doi:10.1001/ jamainternmed.2020.0994.

  4. Zhou YH, Qin YY, Lu YQ, et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial [published online ahead of print, 2020 Mar 5]. Chin Med J (Engl) 2020;10.1097/CM9.0000000000000791. doi:10.1097/ CM9.0000000000000791.

  5. Arabi YM, Alothman A, Balkhy HH, et al. Treatment of middle east respiratory syndrome with a combination of lopinavirritonavir and interferon-¦Â1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials 2018;19(1):81. Published 2018 Jan 30. doi:10.1186/s13063-017-2427-0.

  6. Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression [published online ahead of print, 2020 Mar 12]. Int J Infect Dis 2020;S1201-9712(20)30132-6. doi:10.1016/j.ijid.2020.03.013.

  7. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 [published online ahead of print, 2020 Mar 18]. N Engl J Med 2020;10.1056/ NEJMoa2001282. doi:10.1056/NEJMoa2001282.

  8. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [published online ahead of print, 2020 Mar 9]. Clin Infect Dis 2020;ciaa237. doi:10.1093/cid/ciaa237.

  9. Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020;43(3):185-188. doi:10.3760/cma .j.issn.1001-0939.2020.03.009.

  10. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics [published online ahead of print, 2020 Mar 4]. Drug Dev Res 2020;10.1002/ddr.21656. doi:10.1002/ddr.21656.

  11. Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws [published online ahead of print, 2020 Mar 21]. Oral Oncol 2020;104659. doi:10.1016/j. oraloncology.2020.104659.

  12. Xu X, Han M, Li T et al. Effective treatment of severe COVID- 19 patients with tocilizumab. chinaXiv:202003.00026v1 (2020). www.chinaxiv.org/abs/202003.00026.

  13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G, 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;1-3.

  14. Zhaowei Chen, Jijia Hu, Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang, Ben Hu, Zhan Zhang. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv 2020.03.22.20040758. doi: https://doi.org/10.1101/202 0.03.22.20040758.

  15. Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Morgane Mailhe, Barbara Doudier, Johan Courjon, Valerie Giordanengo, Vera Esteves Vieira, Herv¨¦ Tissot Dupont, St¨¦phane Honor¨¦, Philippe Colson, Eric Chabriere, Bernard La Scola, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial. Int J Antimicrob Agents 2020. doi: https://doi.org/10.1016/j.ijantimicag.2020.105949.

  16. Wei Cao, Xiaosheng Liu, Tao Bai, Hongwei Fan, Ke Hong, Hui Song, Yang Han, Ling Lin, Lianguo Ruan, Taisheng Li. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum Infectious Diseases ofaa102. https:// doi.org/10.1093/ofid/ofaa102.




2020     |     www.medigraphic.com